The Trump administration proceeds with the third cycle of Medicare drug price negotiations, addressing Part B drug inclusion and sparking pharmaceutical industry concerns about pricing and implementation.

Tariffs on medical imports have led U.S. health plans to plan premium increases for 2025 due to rising drug and device costs, impacting payer pricing strategies and market outlooks.